



Research Collaboration Opportunity

Title: A safer, more effective clot-dissolving drug: Xai-K

PIs

Dr. Ed Pryzdial

Therapeutic Area

Thrombosis

Description

Xai-K rapidly dissolves clots as a primary therapeutic. It can also be used in combination with the prevailing thrombolytic drug, tPA, enabling reduced dosages to improve the safety profile of the latter for treatment of resistant thrombi. To avoid reocclusion, Xai-K was designed to dually function as an anticoagulant.

Research stage

The efficacy of Xai-K as both a primary and adjunctive therapeutic has been demonstrated in a pre-clinical murine model of occlusive thrombosis. Using Rayleigh light scattering, thomboelastography and numerous other in vitro techniques, its biochemistry has been analyzed.

Types of collaborations

Interested in a pharmaceutical partner that could fund and/or advise our studies on producing a recombinant version of Xai-K and to optimize the chemical composition of the modification that confers thrombolytic activity.

IP Status

Patents have been submitted in the US and Europe.

Contact

Dr. Ed Pryzdial

Scientist, Canadian Blood Services, Centre for Innovation

Associate Director, Centre for Blood Research

Clinical Professor, Department of Pathology and Laboratory Medicine

Associate Director, Exams, Graduate Studies Program

2350 Health Sciences Mall, Centre for Blood Research, Rm 4365

Life Sciences Centre, University of British Columbia,

Vancouver, Canada, V6T 1Z3

604-822-3823

<http://cbr.ubc.ca/people/investigators/ed-pryzdial/>